Skip to content
English
  • There are no suggestions because the search field is empty.

Asthma Exacerbation Aftercare

Following a mild asthma exacerbation, optimal aftercare should address inhaler technique, medication duration, and clear criteria for escalation of care.

 

1. Inhaler Use and Technique

- All patients should receive hands-on education and demonstration of correct inhaler technique, as improper use is common and associated with poor outcomes. Repeated assessment and retraining at every visit are recommended.[1][2][3]

- For pressurized metered-dose inhalers (pMDIs): Shake well, exhale fully, seal lips around the mouthpiece, actuate the inhaler while inhaling slowly and deeply, hold breath for 10 seconds, then exhale.[3]

- For dry powder inhalers (DPIs): Exhale fully away from the device, seal lips around the mouthpiece, inhale rapidly and deeply, hold breath for 10 seconds, then exhale.[3]

- Use a spacer with pMDIs if available, especially for those with coordination difficulties.[2]

2. Duration and Regimen of Prescribed Medication

- For adults and adolescents with mild asthma, the preferred reliever is a low-dose ICS–formoterol combination inhaler used as needed for symptom relief, as recommended by GINA and supported by the American Thoracic Society and the American Academy of Allergy, Asthma, and Immunology.[4][5][6][7]

- If prescribed, as-needed ICS–formoterol: 1 inhalation with each episode of symptoms, not exceeding 8–12 inhalations per day (depending on the specific product and age group).[8][4][5]

- If prescribed, as-needed combination albuterol–budesonide: 1–2 inhalations as needed for symptoms, not exceeding the maximum daily dose per product labeling.[7]

- If a SABA (albuterol) is used as reliever, instruct the patient to take an inhaled corticosteroid (ICS) with each SABA dose, as recommended by the American Thoracic Society and the American Academy of Allergy, Asthma, and Immunology.[4][6]

- Continue the prescribed regimen until symptoms and peak flow return to baseline, typically for several days after the exacerbation.[9]

3. Warning Signs Requiring Immediate Emergency Evaluation

- Advise patients to seek emergency care if they experience any of the following:

- Severe shortness of breath or difficulty speaking in full sentences

- Use of accessory muscles or chest retractions

- Lack of improvement or worsening symptoms after reliever use

- Peak expiratory flow (PEF) <50% of personal best or predicted

- Cyanosis (bluish lips or face), confusion, or drowsiness

- Need for reliever inhaler more frequently than every 4 hours or exceeding maximum recommended daily doses[10][4][5][9]

- Written asthma action plans should be provided, with clear instructions for home management and when to escalate care.[10][5]

4. Follow-Up and Education

- Schedule follow-up within 1–2 weeks to reassess control, inhaler technique, and adherence, and to consider stepping up maintenance therapy if indicated.[10][5][8]

- Educate on trigger avoidance and reinforce the importance of adherence to controller therapy to reduce future exacerbation risk.[5][8][6]

These recommendations are consistent with the most recent evidence and guideline updates, emphasizing the superiority of ICS-containing reliever regimens over SABA-only approaches and the critical role of patient education and follow-up in preventing recurrent exacerbations.

References

  1. Interventions to Improve Inhaler Technique for People With Asthma. Normansell R, Kew KM, Mathioudakis AG. The Cochrane Database of Systematic Reviews. 2017;3:CD012286. doi:10.1002/14651858.CD012286.pub2.
  2. Inhalation Devices, Delivery Systems, and Patient Technique. Nelson HS. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology. 2016;117(6):606-612. doi:10.1016/j.anai.2016.05.006.
  3. Asthma and Chronic Obstructive Pulmonary Disease Inhalers: Techniques for Proper Use. Pepper AN, Cooke A, Livingston L, Lockey RF. Allergy and Asthma Proceedings. 2016;37(4):279-90. doi:10.2500/aap.2016.37.3954.
  4. 2020 Focused Updates to the Asthma Management Guidelines: A Report From the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. Cloutier MM, Baptist AP, Blake KV, et al. The Journal of Allergy and Clinical Immunology. 2020;146(6):1217-1270. doi:10.1016/j.jaci.2020.10.003.
  5. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. Reddel HK, Bacharier LB, Bateman ED, et al. American Journal of Respiratory and Critical Care Medicine. 2022;205(1):17-35. doi:10.1164/rccm.202109-2205PP.
  6. Questions in Mild Asthma: An Official American Thoracic Society Research Statement. Mohan A, Lugogo NL, Hanania NA, et al. American Journal of Respiratory and Critical Care Medicine. 2023;207(11):e77-e96. doi:10.1164/rccm.202304-0642ST.
  7. As-Needed Albuterol–Budesonide in Mild Asthma. LaForce C, Albers F, Danilewicz A, et al. The New England Journal of Medicine. 2025;. doi:10.1056/NEJMoa2504544.
  8. Asthma in Adults. Mosnaim G. The New England Journal of Medicine. 2023;389(11):1023-1031. doi:10.1056/NEJMcp2304871.
  9. Management of Acute Asthma Exacerbations. Pollart SM, Compton RM, Elward KS. American Family Physician. 2011;84(1):40-7.
  10. Acute Asthma Exacerbations: Management Strategies. Dabbs W, Bradley MH, Chamberlin SM. American Family Physician. 2024;109(1):43-50.